112 completed, 24 terminated, 22 recruiting, 21 unknown. 188 Phase 3, 20 Phase 2.
Follow Thromboembolism: new trials by email Literature Review of Thromboembolism trials Research Report on Thromboembolism
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Collaborative Risk-stratified Investigation in Thrombosis-prone Inpatients With Critical Illness: Anticoagulation With LMWH in Teens for ThromboProphylaxis (CRITICAL-Teens-TP). Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Not yet recruiting | Johns Hopkins All Children's Hospital | 802 | 2027-04-15 | 2026-05-26 |
| TicAgreLor Versus Placebo to Prevent Cerebral ISCHemia in anEuRysmal Low Grade SAH A Double Blinded Randomised Controlled Study Experimental group: ticagrelor, Control group: placebo - Subarachnoid Hemorrhage, Aneurysmal, Brain Ischemia | Phase 3 | Not yet recruiting | University Hospital, Toulouse | 274 | 2026-11-24 | 2026-11-06 |
| Venous Thromboembolism (VTE) Prophylaxis With REGN7508 and REGN9933 in Adult and Adolescent Participants With a Peripherally Inserted Central Catheter (PICC) REGN7508, REGN9933, Placebo - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1908 | 2026-09-07 | 2026-09-29 |
| Treatment and Secondary Prevention of Venous Thromboembolism (VTE) in Adult Participants With Solid and Hematologic Cancers REGN7508, Apixaban - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1600 | 2026-08-26 | 2026-11-05 |
| The PARTUM Trial: Postpartum Aspirin to Reduce Thromboembolism Undue Morbidity Aspirin, Low-molecular-weight heparin - Venous Thromboembolism, Postpartum Period | Phase 3 | Recruiting | University of Calgary | 8805 | 2026-06-04 | 2026-07-27 |
| Design and Rationale of the COLT Study Colchicine 0.5 MG Oral Tablet, Placebo - Venous Thrombosis Deep (Limbs), Post-thrombotic Syndrome | Phase 3 | Not yet recruiting | Azienda Sanitaria Locale ASL 6, Livorno | 940 | 2026-06-01 | 2026-02-25 |
| Stroke and Systemic Embolism Prevention in Adult Participants With Atrial Fibrillation for Whom Oral Anticoagulation is Unsuitable REGN7508, REGN9933, Placebo - Atrial Fibrillation (AF) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2628 | 2026-04-03 | 2026-11-10 |
| REGN7508 in Adult Participants for Prevention of Cancer-Associated Thrombosis REGN7508, Placebo - Cancer-Associated Thrombosis (CAT) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 1120 | 2026-03-09 | 2026-11-05 |
| Efficacy and Safety of Tenecteplase Bridging Mechanical Thrombectomy for Acute Large Vessel Occlusion Stroke Tenecteplase, Alteplase - Stroke, Ischemic, Stroke, Acute | Phase 3 | Recruiting | Xuanwu Hospital, Beijing | 850 | 2025-12-25 | 2026-04-09 |
| The Effect of Kinisoquin™ on Thromboembolic Events in Patients With Metastatic or Locally Advanced Pancreatic Cancer Kinisoquin™, Placebo - Venous Thromboembolism, Metastatic Pancreatic Cancer | Phase 3 | Recruiting | Quercis Pharma AG | 480 | 2025-12-19 | 2026-02-02 |
| Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention rivaroxaban and ASA, Low-molecular weight heparin, Fondaparinux - Hip Fracture Surgery, Cardiovascular Prevention | Phase 3 | Not yet recruiting | McMaster University | 100 | 2025-12-01 | 2025-11-14 |
| Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves Rivoroxaban, Warfarin - Valvular Heart Disease Patients | Phase 3 | Enrolling by invitation | Rawalpindi Institute of Cardiology | 60 | 2025-11-13 | 2026-03-16 |
| DOAC - Dosing Options in AntiCoagulation Prophylaxis Apixaban 2.5 mg twice daily, Apixaban 5 mg once daily, No anticoagulation - Cancer, VTE (Venous Thromboembolism) | Phase 3 | Recruiting | University of Vermont | 996 | 2025-10-17 | 2026-02-05 |
| Short-term Low-dose Low-molecular-weight Heparin to Prevent Postpartum Thrombosis Low-dose low-molecular-weight heparin - Venous Thromboembolism (VTE), Postpartum | Phase 3 | Recruiting | Marc Blondon | 9200 | 2025-10-15 | 2026-10-06 |
| Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma Aspirin 100mg, Rivaroxaban 10mg - Multiple Myeloma, Venous Thromboembolism | Phase 3 | Not yet recruiting | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 530 | 2025-09-01 | 2025-07-18 |
| Colchicine to Quench the Inflammatory Response After Deep Vein Thrombosis (The Conquer-DVT Pilot Trial) Colchicine 0.5 mg po, Placebo 0.5 mg po - Venous Thromboembolism | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 150 | 2025-07-07 | 2026-07-23 |
| REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults REGN7508, Apixaban, Enoxaparin - Venous Thromboembolism (VTE) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 2000 | 2025-06-25 | 2026-11-06 |
| Anti-Xa Guided Dosing of Low Molecular Weight Heparin for Prevention of Venous Thromboembolism Following Traumatic Injury: a Multicentre Pilot Randomized Trial Anti-Xa Guided Dosing of Low Molecular Weight Heparin, Standard of Care Dosing - Venous Thromboembolism (VTE), Trauma Related Injuries | Phase 2 / Phase 3 | Unknown | Alexandre Tran | 150 | 2025-01-01 | 2024-10-28 |
| Reducing Gastrointestinal Bleeding With Proton Pump Inhibitor Therapy in Acute Venous Thromboembolism Omeprazole 20 mg Oral Tablet, Placebo - Venous Thromboembolism, Gastro Intestinal Bleeding | Phase 3 | Recruiting | Ottawa Hospital Research Institute | 360 | 2024-11-06 | 2026-07-22 |
| VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy Rivaroxaban 10 MG, Placebo control - Venous Thromboembolism, Urologic Cancer | Phase 2 / Phase 3 | Recruiting | Ottawa Hospital Research Institute | 120 | 2024-11-04 | 2026-11-12 |
Showing 20 of 188. Sign in to see all of them.
Venous Thromboembolism (132) · Venous Thrombosis (45) · Pulmonary Embolism (39) · Thrombosis (22) · Neoplasms (15) · Hemorrhage (14) · Stroke (11) · Intracranial Thrombosis (10) · Atrial Fibrillation (9) · Postthrombotic Syndrome (5) · Embolism (4) · Pancreatic Neoplasms (4) · Cardiovascular Diseases (3) · Cerebrovascular Disorders (3)
Vascular Diseases (187) · Embolism and Thrombosis (186) · Cardiovascular Diseases (185) · Respiratory Tract Diseases (45) · Lung Diseases (43) · Pathological Conditions, Signs and Symptoms (42) · Thrombosis (41) · Pathologic Processes (40) · Embolism (39) · Brain Diseases (26) · Central Nervous System Diseases (26) · Nervous System Diseases (26) · Cerebrovascular Disorders (22) · Neoplasms (17)
Enoxaparin (42) · Rivaroxaban (38) · Warfarin (20) · Dabigatran (16) · Dalteparin (16) · Aspirin (13) · Heparin, Low-Molecular-Weight (13) · apixaban (13) · Fondaparinux (11) · enoxaparin sodium (11) · Tinzaparin (9) · AVE 5026 (7) · edoxaban (7) · Heparin (6) · Nadroparin (6)
Bayer (13) · Boehringer Ingelheim (11) · Sanofi (10) · GlaxoSmithKline (7) · Ottawa Hospital Research Institute (7) · University Hospital, Brest (7) · Astellas Pharma Inc (6) · McMaster University (6) · Regeneron Pharmaceuticals (5) · Daiichi Sankyo Co., Ltd. (4) · Crux Biomedical (3) · Daiichi Sankyo (3) · Hamilton Health Sciences Corporation (3) · Janssen Research & Development, LLC (3) · Kafrelsheikh University (3)
United States (70) · Canada (65) · France (47) · Italy (43) · Germany (39) · Spain (35) · Netherlands (33) · Denmark (31) · Russia (31) · Czechia (30) · Poland (30) · Australia (28) · Belgium (28) · Brazil (28) · Sweden (28)
Alexander Turpie, MD (3) · Giancarlo Agnelli, MD (3) · Takeshi Fuji (3) · Francis Couturaud, MD, PhD (2) · Guy Meyer, MD (2) · Jim Julian, MMath (2)
PMID 33337539, PMID 24081972, PMID 22429800, PMID 22709460, PMID 27807306, PMID 32657973, PMID 18190818, PMID 22995531, PMID 23425163, PMID 24344086, PMID 26578849, PMID 27980462, PMID 28617144, PMID 28762617, PMID 31867054, PMID 31975354, PMID 34172290, PMID 34755519, PMID 34878173, PMID 35389229, PMID 35876829, PMID 36150047, PMID 38348778, PMID 38844941, PMID 40163217, PMID 16537663, PMID 16537725, PMID 16926353, PMID 17723125, PMID 17869635, PMID 18042917, PMID 18402906, PMID 18485453, PMID 18579811, PMID 18579812, PMID 18582928, PMID 19411100, PMID 19721013, PMID 19726226, PMID 19807917, PMID 19825809, PMID 19854398, PMID 19966341, PMID 20047905, PMID 20124123, PMID 20448094, PMID 21128814, PMID 21225098, PMID 21315215, PMID 21359646
2014 (5), 2005 (3), 2015 (3), 2016 (3), 2023 (3), 2025 (3), 2004 (2), 2008 (2), 2009 (1), 2019 (1), P30CA015083 (1), R01HD106326 (1), R01HL033233 (1), R01HL057951 (1), R01HL095109 (1)